🔗 Share this article World Health Organization Issues Concern Over Critical Shortage of Obesity Jabs Less than a tenth of patients who could benefit from obesity jabs like Wegovy can access them, warns the global health agency as it releases its first guidance on the drugs. With more than one billion people worldwide now living with obesity, it is calling for increased and just access to these injectable treatments. Per projections, over two billion are projected to be obese by 2030 without intervention. "The new guidelines affirms that excess weight is a lifelong illness that can be treated with thorough and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus. High costs, insufficient output, and logistical bottlenecks are significant barriers to universal access to the treatments that can assist patients in reducing considerable weight, explains the organization. Weight-Loss Drug Supply Crisis Even in the current most favorable case, the manufacturing of such drugs could only cover about 100 million people – less than 10% of those who need them, per the WHO. The advice encourages governments and firms to expand access, through strategies such as voluntary licensing. A patent on the active ingredient – the primary component of a leading brand – is scheduled to end in multiple nations in 2026. The Way Obesity Jabs Function These medications mimick a body's own hormone to delay gastric emptying, reduce hunger and enhance satiety so users reduce food intake. People usually see weight reduction in the initial weeks of commencing the weekly injections. Evidence points to users may put most of the weight back on after a year of discontinuing the treatment, as their typical appetite come back. Being overweight or obese elevates your risk for contracting medical conditions, like diabetes, cardiovascular issues, stroke, and certain cancers. Obesity impacts individuals in every country and was associated with millions of fatalities worldwide in 2024, according to the health agency.
Less than a tenth of patients who could benefit from obesity jabs like Wegovy can access them, warns the global health agency as it releases its first guidance on the drugs. With more than one billion people worldwide now living with obesity, it is calling for increased and just access to these injectable treatments. Per projections, over two billion are projected to be obese by 2030 without intervention. "The new guidelines affirms that excess weight is a lifelong illness that can be treated with thorough and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus. High costs, insufficient output, and logistical bottlenecks are significant barriers to universal access to the treatments that can assist patients in reducing considerable weight, explains the organization. Weight-Loss Drug Supply Crisis Even in the current most favorable case, the manufacturing of such drugs could only cover about 100 million people – less than 10% of those who need them, per the WHO. The advice encourages governments and firms to expand access, through strategies such as voluntary licensing. A patent on the active ingredient – the primary component of a leading brand – is scheduled to end in multiple nations in 2026. The Way Obesity Jabs Function These medications mimick a body's own hormone to delay gastric emptying, reduce hunger and enhance satiety so users reduce food intake. People usually see weight reduction in the initial weeks of commencing the weekly injections. Evidence points to users may put most of the weight back on after a year of discontinuing the treatment, as their typical appetite come back. Being overweight or obese elevates your risk for contracting medical conditions, like diabetes, cardiovascular issues, stroke, and certain cancers. Obesity impacts individuals in every country and was associated with millions of fatalities worldwide in 2024, according to the health agency.